Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director | May 20, 2026 | May 22, 2026 |
| MYRIAD GENETICS INCMYGN · Entity 5953 | Director | June 04, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,446 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 671 · Balance 1,446 F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $298.48 · Expires 2036-05-20 | Direct | 1,441 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 1,441 · Balance 1,441 F2: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
F2: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
MYRIAD GENETICS INC
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 152,030 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 59,701 · Balance 152,030 F1: Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 5, 2026 20:25 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 59,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001740730-26-000002 · wk-form4_1780691097.xml · nonDerivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,030 F1 · shares: Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:16 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (Right to Buy) · Derivative | 1,441 | $0.00 Strike: $298.48 | $0.00 |
DisclosureSEC source: 0001178670-26-000040 · form4.xml · derivative · entry 2 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,441 Underlying: Common Stock · 1,441 shares Expires 2036-05-20 F2 · derivative.exercise_date: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:16 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 671 | $0.00 | $0.00 |
DisclosureSEC source: 0001178670-26-000040 · form4.xml · nonDerivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,446 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $100.65 | $0.00 |
DisclosureSEC source: 0001735276-25-000097 · edgardoc.xml · derivative · entry 18 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2028-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on June 10, 2025. F17 · derivative.exercise_date: This stock option was fully vested and exercisable as of June 1, 2021. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 25 | $480.98 | $12,024.50 |
DisclosureSEC source: 0001735276-25-000097 · edgardoc.xml · nonDerivative · entry 17 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 775 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on June 10, 2025. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,386 | $479.55 | $664,656.30 |
DisclosureSEC source: 0001735276-25-000097 · edgardoc.xml · nonDerivative · entry 16 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 800 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on June 10, 2025. F16 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $479.35 to $479.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,450 | $478.67 | $694,071.50 |
DisclosureSEC source: 0001735276-25-000097 · edgardoc.xml · nonDerivative · entry 15 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,186 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on June 10, 2025. F15 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $478.33 to $479.30. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,183 | $477.47 | $564,847.01 |
DisclosureSEC source: 0001735276-25-000097 · edgardoc.xml · nonDerivative · entry 14 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,636 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on June 10, 2025. F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $477.05 to $477.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 972 | $476.31 | $462,973.32 |
DisclosureSEC source: 0001735276-25-000097 · edgardoc.xml · nonDerivative · entry 13 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,819 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on June 10, 2025. F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $475.85 to $476.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 951 | $474.85 | $451,582.35 |
DisclosureSEC source: 0001735276-25-000097 · edgardoc.xml · nonDerivative · entry 12 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,791 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on June 10, 2025. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $474.58 to $475.06. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 838 | $474.22 | $397,396.36 |
DisclosureSEC source: 0001735276-25-000097 · edgardoc.xml · nonDerivative · entry 11 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,742 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on June 10, 2025. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $473.48 to $474.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 823 | $472.82 | $389,130.86 |
DisclosureSEC source: 0001735276-25-000097 · edgardoc.xml · nonDerivative · entry 10 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,580 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on June 10, 2025. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $472.37 to $473.30. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 222 | $471.25 | $104,617.50 |
DisclosureSEC source: 0001735276-25-000097 · edgardoc.xml · nonDerivative · entry 9 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,403 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on June 10, 2025. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $470.77 to $471.75. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 799 | $464.36 | $371,023.64 |
DisclosureSEC source: 0001735276-25-000097 · edgardoc.xml · nonDerivative · entry 8 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,625 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on June 10, 2025. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $464.18 to $464.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,652 | $463.00 | $764,876.00 |
DisclosureSEC source: 0001735276-25-000097 · edgardoc.xml · nonDerivative · entry 7 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,424 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on June 10, 2025. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $462.73 to $463.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 2,290 | $461.92 | $1,057,796.80 |
DisclosureSEC source: 0001735276-25-000097 · edgardoc.xml · nonDerivative · entry 6 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,076 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on June 10, 2025. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $461.42 to $462.41. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 473 | $460.71 | $217,915.83 |
DisclosureSEC source: 0001735276-25-000097 · edgardoc.xml · nonDerivative · entry 5 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,366 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on June 10, 2025. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $460.35 to $461.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,403 | $459.73 | $645,001.19 |
DisclosureSEC source: 0001735276-25-000097 · edgardoc.xml · nonDerivative · entry 4 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,839 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on June 10, 2025. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $459.29 to $460.22. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,888 | $458.86 | $866,327.68 |
DisclosureSEC source: 0001735276-25-000097 · edgardoc.xml · nonDerivative · entry 3 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,242 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on June 10, 2025. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $458.22 to $459.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,645 | $457.44 | $752,488.80 |
DisclosureSEC source: 0001735276-25-000097 · edgardoc.xml · nonDerivative · entry 2 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,130 F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on June 10, 2025. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $456.93 to $457.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 18,000 | $100.65 | $1,811,700.00 |
DisclosureSEC source: 0001735276-25-000097 · edgardoc.xml · nonDerivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on June 10, 2025. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:04 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 49,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-029973 · wk-form4_1749240274.xml · nonDerivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,329 F1 · shares: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 1,558 | $0.00 Strike: $258.35 | $0.00 |
DisclosureSEC source: 0001735276-25-000062 · edgardoc.xml · derivative · entry 5 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,558 Underlying: Common Stock · 1,558 shares Expires 2035-05-08 F2 · derivative.exercise_date: The stock option vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000062 · edgardoc.xml · nonDerivative · entry 4 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 775 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| April 16, 2025 Filed May 12, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 36 | $232.86 | $8,382.96 |
DisclosureSEC source: 0001735276-25-000062 · edgardoc.xml · nonDerivative · entry 3 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| October 17, 2024 Filed May 12, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | PurchaseCommon Stock | 4 | $302.67 | $1,210.68 |
DisclosureSEC source: 0001735276-25-000062 · edgardoc.xml · nonDerivative · entry 2 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36 Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 23:38 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 46,012 | $27.95 | $1,285,851.35 |
DisclosureSEC source: 0001628280-24-039405 · wk-form4_1725487777.xml · nonDerivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,533 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.45 to $28.47, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 29, 2024 Filed May 12, 2025 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | PurchaseCommon Stock | 32 | $286.00 | $9,152.00 |
DisclosureSEC source: 0001735276-25-000062 · edgardoc.xml · nonDerivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32 Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:54 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 15,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027331 · wk-form4_1717793637.xml · nonDerivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,545 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant and (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 5,228 | $0.00 Strike: $151.22 | $0.00 |
DisclosureSEC source: 0001735276-24-000049 · edgardoc.xml · derivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,228 Underlying: Common Stock · 5,228 shares Expires 2034-05-16 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 22:11 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 15,151 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-020711 · wk-form4_1685743873.xml · nonDerivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,850 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant and (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 3,454 | $0.00 Strike: $189.87 | $0.00 |
DisclosureSEC source: 0001735276-23-000064 · edgardoc.xml · derivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,454 Underlying: Common Stock · 3,454 shares Expires 2033-05-18 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 21:25 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 17,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-016217 · wf-form4_165429154410113.xml · nonDerivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,699 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the Date of Grant and (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 5,153 | $0.00 Strike: $128.31 | $0.00 |
DisclosureSEC source: 0001735276-22-000052 · edgardoc.xml · derivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,153 Underlying: Common Stock · 5,153 shares Expires 2032-05-17 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 4,032 | $0.00 Strike: $171.95 | $0.00 |
DisclosureSEC source: 0001735276-21-000070 · edgardoc.xml · derivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,032 Underlying: Common Stock · 4,032 shares Expires 2031-07-14 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 23:43 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 12,848 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022153 · doc4.xml · nonDerivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,424 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests on the anniversary of the date of grant. Read SEC document |
| December 04, 2020 Filed Dec 7, 2020 23:44 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 15,889 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032908 · doc4.xml · nonDerivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,576 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 20:50 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 4,581 | $0.00 Strike: $148.77 | $0.00 |
DisclosureSEC source: 0001735276-20-000075 · edgardoc.xml · derivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,581 Underlying: Common Stock · 4,581 shares Expires 2030-07-01 Read SEC document |
| December 05, 2019 Filed Dec 6, 2019 20:25 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 11,687 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-028658 · doc4.xml · nonDerivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,687 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $72.01 | $0.00 |
DisclosureSEC source: 0001735276-19-000064 · edgardoc.xml · derivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-30 Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:44 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $100.65 | $0.00 |
DisclosureSEC source: 0001735276-18-000011 · edgardoc.xml · derivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-06-01 F1 · derivative.exercise_date: The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.